{"entity":{"id":"nct05757336","kind":"trial","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","aka":[],"tldr":"A phase 2 trial of sintilimab, gemcitabine, nab-paclitaxel and bevacizumab in gallbladder cancer, run by Lu Wang, MD, PhD, now recruiting.","summary":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer is a phase 2 interventional study registered as NCT05757336 by Lu Wang, MD, PhD, with a registry enrolment figure of 50 participants, started 2022-12-22 and due to reach its primary completion in 2024-12-22. Interventions recorded: Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab. Conditions listed: Gallbladder Cancer, Initially Unresectable, the First Line Treatment. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05757336","url":"https://clinicaltrials.gov/study/NCT05757336"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","monoclonal-antibody"],"targets":[],"drugs":["sintilimab","gemcitabine","nab-paclitaxel","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05757336","phase":"2","setting":"Explore the Efficacy and Safety of Sintilimab Plus Bevacizumab Combined With Gemcitabine and Albumin-paclitaxel (AG Regimen) in First-line Treatment of Initial Unresectable Gallbladder Cancer: a Phase II Clinical Study","sponsor":"Lu Wang, MD, PhD","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05757336/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}